Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

3152 results found

2022 ∙ Goodman, E. Reuschenbach, M. Kaminski, A. Ronnebaum, S.

Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review

  • All age groups
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Whitehouse, E. R. Mandra, A. Bonwitt, J. Beasley, E. A. Taliano, J. Rao, A. K.

Human rabies despite post-exposure prophylaxis: a systematic review of fatal breakthrough infections after zoonotic exposures

  • All age groups
  • Rabies
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Schietzel, S. Anderegg, M. Limacher, A. Born, A. Horn, M. P. Maurer, B. Hirzel, C. Sidler, D. Moor, M. B.

Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Meshram, H. S. Kute, V. Rane, H. Dave, R. Banerjee, S. Mishra, V. Chauhan, S.

Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: A systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
High
2022 ∙ Bailey, A. J. M. Maganti, H. B. Cheng, W. Shorr, R. Arianne Buchan, C. Allan, D. S.

Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2022 ∙ Yoo, J. J. Yon, D. K. Lee, S. W. Shin, J. I. Kim, B. K.

Humoral Immunogenicity to SARS-CoV-2 Vaccination in Liver Transplant Recipients: A Systematic Review and Meta-Analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Martins-Branco, D. Nader-Marta, G. Tecic Vuger, A. Debien, V. Ameye, L. Brandão, M. Punie, K. Loizidou, A. Willard-Gallo, K. Spilleboudt, C. Awada, A. Piccart, M. de Azambuja, E.

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

  • Adolescents
  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Müller, K. E. Dohos, D. Sipos, Z. Kiss, S. Dembrovszky, F. Kovács, N. Solymár, M. Erőss, B. Hegyi, P. Sarlós, P.

Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients

  • Adults
  • Older adults
  • Pneumococcal disease
  • Influenza
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Shoar, S. Prada-Ruiz, A. C. C. Patarroyo-Aponte, G. Chaudhary, A. Sadegh Asadi, M.

Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Xiao, Karren Gillissie, Emily S. Lui, Leanna M. W. Ceban, Felicia Teopiz, Kayla M. Gill, Hartej Cao, Bing Ho, Roger Rosenblat, Joshua D. McIntyre, Roger S.

Immune Response to Vaccination in Adults with Mental Disorders: A Systematic Review

  • Adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...